Man wearing tiny red lanterns beside a lake, where his reflection becomes a meadow with new growth.
Back to the library

Recovery

Red light and hair

Red light at around 630 to 680 nm has been tested for pattern hair loss using scalp-contact helmets, caps and combs, and sham-controlled trials plus a 2019 meta-analysis reported increased hair counts and density compared with sham. Those devices sit directly on the scalp and were used every other day for four months or more. A standing panel delivers a much lower dose to the scalp, filtered through whatever hair is already there, and has not been tested for this. The evidence is for the dedicated devices, not for a panel session.

Evidence so far
Moderate
Reading timeAbout 12 minutes

Start here

Why this is being studied

This path is about androgenetic alopecia, the gradual thinning of hair on the scalp that affects a large share of adults. Red light at roughly 630 to 680 nm is absorbed within the first few millimetres of tissue, which is where hair follicles sit, making the scalp one of the few targets a red light dose can reach reliably. The proposal is that light absorbed by mitochondria in and around the follicle may support a longer active growth phase, and this is one of the better-tested uses, provided the device is held against the scalp.

Where the evidence stands

Flag text

The mechanism

What is going on, and why this might help

What is going on in a thinning scalp

Each hair follicle cycles through a long active growth phase, a short transition and a resting phase before the hair is shed. In androgenetic alopecia the growth phase shortens with each cycle and follicles progressively miniaturise, producing finer, shorter hairs until they stop producing visible hair at all. The follicle is usually still there, which is why interventions aim to extend the growth phase rather than create new follicles.

What the light is absorbed by

Cytochrome c oxidase in the mitochondria of follicular cells absorbs red light at 630 to 680 nm. The model is the standard one: absorbed photons displace inhibitory nitric oxide from the enzyme, oxygen use and ATP production rise briefly, the nitric oxide released locally relaxes small vessels and increases blood flow to the follicle, and a low-level burst of reactive oxygen species acts as a signal rather than as damage, activating transcription factors linked to growth factor release and proliferation. In the reviews of this use, the proposed result is a longer active growth phase and reduced miniaturisation.

The biphasic dose response

Scalp devices use modest doses delivered frequently over months, typically on alternate days for sixteen weeks or longer in the trials. That schedule is the thing the evidence actually supports. Above the working window the response curve falls, so more intense or longer sessions are not a shortcut, and no trial has tested daily high-dose exposure as a way of speeding results.

How far the light actually goes

Hair follicles sit a few millimetres into the scalp, comfortably within reach of red light where the light can get there. The practical obstacle is hair itself, which absorbs and scatters light before it reaches the skin, and distance. The trial devices were helmets, caps and combs placed in contact with the scalp, often parting the hair. A panel a foot or more away, angled at the body rather than the crown, delivers a small fraction of that to the scalp. This is why the evidence is graded moderate for dedicated scalp devices and early for panels.

Explainer illustration

The studies

Every study is laid out the same way: what the researchers wanted to find out, who took part, what they actually did, what they found, why it might work and where the limits are. No jargon, and a link to the original if you want to read it yourself.

Each study is laid out the same way: what the researchers asked, who took part, what they did, what they found, why it might work, and where the limits are. The clinician layer at the end of each one carries the numbers.

Paper 1

The growth of human scalp hair mediated by visible red light laser and LED sources in males

Lanzafame et al. · Lasers in Surgery and Medicine · 2013 · Randomised double-blind sham-controlled trial in men

Read the paper

What they asked

Devices claiming to grow hair with red light had been on sale for years on the strength of thin evidence. This American team asked a straightforward question under proper conditions: over sixteen weeks, does a 655 nm scalp device increase the number of hairs in a defined area of scalp compared with an identical device that emits no therapeutic light.

Who took part

Men with androgenetic alopecia, the common pattern of hair thinning, were recruited and randomly allocated to an active or a sham device. Both the men and the assessors counting hairs were kept unaware of which device was which, which matters a great deal here because hair counts done by someone who knows the allocation are easy to influence. People using other hair loss treatments were excluded so the effect could be attributed to the light.

What they did

Participants used the device at home on alternate days over sixteen weeks. Active devices delivered 655 nm red light from laser and LED sources directly against the scalp; sham devices were identical in appearance and operation. The main outcome was terminal hair count in a marked area of scalp, measured from standardised macro photographs before and after, counted by assessors who did not know the allocation.

What they found

Researchers found a significantly greater increase in terminal hair count in the active group than in the sham group over sixteen weeks. No serious adverse effects were reported, and the device was well tolerated in home use.

What it means

This is one of the cleanest trials in the whole red light literature: blinded, sham-controlled, with an outcome that is counted rather than rated. It supports the idea that red light held against the scalp for months may support hair growth in pattern hair loss. Every element of that sentence matters, particularly the contact and the months.

Limits

The trial was industry-linked, as most device trials are, and ran for sixteen weeks with no follow-up after the device was stopped, so it is not known whether any gain persists without continued use. Hair counts in a small marked area are a proxy for how hair looks overall. The trial studied men with a specific pattern of loss and does not speak to hair thinning from other causes. It tested one wavelength and one device held on the scalp.

Paper 2

Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a systematic review and meta-analysis of randomized controlled trials

Liu et al. · Lasers in Medical Science · 2019 · Systematic review and meta-analysis of randomised controlled trials

Read the paper

What they asked

Several individual device trials had reported positive results, most of them funded by the companies that made the devices. This review asked whether, pooled across all the randomised controlled trials available, low-level light increases hair density compared with sham, and whether the effect varies by device type, wavelength or treatment schedule.

Who took part

The review pooled randomised controlled trials in adults with androgenetic alopecia, including both men and women. Individual trials were of modest size, typically several dozen to a couple of hundred participants, and all compared an active scalp device against a sham device rather than against no treatment.

What they did

The reviewers searched the literature systematically, assessed the trials for risk of bias, and pooled hair density outcomes measured by standardised photography or phototrichogram. They also compared subgroups by wavelength and by the type of device used, whether helmet, cap or comb.

What they found

The pooled analysis reported that low-level light increased hair density compared with sham across the included trials. The reviewers noted variation between devices and schedules, and that the trials were generally short and frequently supported by manufacturers.

What it means

Pooling independent sham-controlled trials and finding the same direction of effect is what moves a use from early to moderate. It supports hair as one of the better-evidenced red light applications, alongside skin and oral mucositis, and for the same reason: the target is shallow and the device is held right against it.

Limits

Manufacturer involvement runs through most of the underlying trials, which is a real concern when the effects are modest. Follow-up is short in almost all of them, so durability after stopping is unknown. Hair density measured in a marked patch is not the same as visible improvement. Nothing in the review tests panels, and the doses the scalp receives from a contact helmet and from a panel across a room are not comparable.

Paper 3

The growth of human scalp hair in females using visible red light laser and LED sources

Lanzafame et al. · Lasers in Surgery and Medicine · 2014 · Randomised double-blind sham-controlled trial in women

Read the paper

What they asked

Most hair loss research has been done in men, and pattern hair loss in women differs in how it presents and how it is usually managed. This companion trial asked whether the same 655 nm scalp device that had been tested in men would increase hair counts in women with androgenetic alopecia compared with a sham device.

Who took part

Women with androgenetic alopecia were recruited and randomly allocated to an active or a sham device, with both participants and assessors kept unaware of the allocation. As in the men's trial, people using other hair loss treatments were excluded so that any change could be attributed to the light.

What they did

The protocol mirrored the earlier trial: home use of the device on alternate days over sixteen weeks, with 655 nm light delivered directly against the scalp by the active device and an identical-looking sham for comparison. Terminal hair counts in a marked scalp area were measured from standardised photographs by blinded assessors.

What they found

The trial reported a significantly greater increase in terminal hair count in the active group than in the sham group over the sixteen weeks, consistent with the earlier result in men. The device was well tolerated.

What it means

A replication of the same design in a different group, by the same team, pointing the same way. That is a meaningful addition, and it is the reason the hair literature covers both men and women rather than only men. It carries the same conditions as its predecessor: a device against the scalp, on alternate days, for four months.

Limits

Replication by the same research team with the same industry links is weaker than replication by an independent group. The trial was again sixteen weeks with no follow-up after stopping. Pattern hair loss in women has several contributing causes, and the trial cannot say which participants had which. Hair counted in a marked area remains a proxy for overall appearance.